Board summary
Key figures
36,913
Registered population
55.6% aged 18–64
24.5%
Aged 65+
ICB 19.9% · England 17.9%
6.0%
Ethnic minority (non-White)
2.2% Asian · England 9.6%
0.5%
In IMD quintile 1
ICB 17.1% · England 21.0%
~182
Core20 residents (est.)
Resident basis; registered basis ~240 · see page 3
6,437
Hypertension register
+7.44% in 3 yrs · England +5.60%
237
SMI register
14% of Maidstone's
572
COPD register
Reviews +15.06% in 3 yrs
Forecast to 2030
7,723
Hypertension patients, 2030
+1,286 on today
78.8%
QRISK ≥20% on statins, 2030
+9.04pp over 3 yrs
6.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension control lags despite high BP recording.
Treatment to target is 65.0% (England 70.3%) after a -5.2% 3-year change, while QRISK ≥ 20% lipid therapy is 55.0% (England 63.6%).
Age-five booster uptake trails first MMR dose.
At age 5, MMR1 reaches 95.5%, but MMR2 is 84.1% (an 11.4 pp difference) and the 4-in-1 booster is 80.7% against the 95.0% target.
Diabetes glycaemic control exceeds national and ICB averages.
HbA1c control reaches 89.4% in patients with frailty (England 81.9%) and 62.2% without frailty (England 57.4%), alongside 86.2% SMI blood pressure checks.
Population, age and ethnicity
An older population profile with 24.5% aged 65+ may drive higher frailty needs
THE RIDGE PCN has 36,913 registered patients. Patients aged 65+ make up 24.5% (9,044), above Maidstone (18.7%), NHS Kent and Medway ICB (19.9%) and England (17.9%). Adults aged 18–64 comprise 55.6% (20,537), below Maidstone (59.8%), ICB (59.5%) and England (62.7%). Those aged 0–17 comprise 19.9% (7,332). In associated Census areas, 94.0% are White (Maidstone 89.8%, ICB 88.6%, England 81.1%), and 6.0% are ethnic minorities. Projected population growth to 2030 is 3.1% via unverified methodology. Ethnicity reflects Census residents, not GP registrations.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Maidstone local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Maidstone LA) | 2,653 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 89.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 62.2% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Maidstone LA) | 1,380 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Maidstone LA) | 15.8 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 0.5% network-wide and concentrated entirely in Langley at 7.0%
The PCN records an average IMD decile of 6.4 (Maidstone 5.9, ICB 5.4, England 5.5). Core20 share is 0.5%, below Maidstone (9.9%), the ICB (17.1%), and England (21.0%). Deprivation is concentrated at Langley (7.0% share; 240 estimated patients), while Bearsted, Len Valley Practice, and Sutton Valence Group Practice record 0.0%. Registered estimates (240 patients; weighted share 0.7%) diverge from 182 residents across 1 decile-2 LSOA. Targeted inequalities outreach will achieve greatest reach by prioritising Langley, the practice with Core20 registered patients.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
237
SMI register
0.64% recorded prevalence
227
Learning disability register
0.62% recorded prevalence
16
Care homes, 780 beds
In the PCN catchment
8.7%
Provide unpaid care
Maidstone, Census 2021
Learning disability prevalence is 0.6% (227 patients, matching England) and severe mental illness is 0.6% (237 patients, below England at 1.0%). The catchment holds 16 care homes (780 beds), with 0.8% Gypsy or Irish Traveller residents (England 0.1%). Applying the borough rate yields a modelled ceiling estimate of 3,211 unpaid carers.
Severe mental illness: physical health checks
Recorded SMI prevalence is 0.6% (England 1.0%). Blood pressure checks reached 86.2% (England 83.4%) and BMI recording was 83.2% (England 82.1%). Bearsted recorded 79.1% for blood pressure checks and 74.6% for BMI. Other check elements were not captured.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,437
Hypertension register
+7.44%
Register growth, 3 yrs
Maidstone +4.31% · England +5.60%
−1.17pp
BP control, under 80
≤140/90 · −2.50pp aged 80+
+1,286
More patients by 2030
Forecast 7,723 (20.14%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.4% (6,437 patients), above England (15.2%), Maidstone (16.0%) and NHS Kent and Medway ICB (16.2%). Recent blood pressure checks reached 88.8% (Maidstone 90.4%, England 90.0%). Patients treated to target stands at 65.0% (England 70.3%, Maidstone 69.7%, NHS Kent and Medway ICB 67.7%), following a 3-year change of -5.2% (England +3.6%). Blood pressure control under age 80 is 63.7% (England 67.8%), dropping to 61.1% at Bearsted, while control aged 80+ is 76.7% (England 81.2%). Treatment to target trails national benchmarks across both age cohorts, suggesting medication titration and structured recall could be evaluated to narrow the gap.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 55.0%, below England (63.6%), Maidstone (60.3%) and NHS Kent and Medway ICB (61.4%). Statin therapy for diabetes with history of CVD is 81.0% (England 84.4%, Maidstone 83.3%, NHS Kent and Medway ICB 83.3%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 84,053 | £1.20 | £1.90 | £1.86 | £100,864 |
| Cardiovascular (all), 2025 | 114,397 | £2.30 | £3.57 | £3.33 | £263,113 |
In 2026, the PCN prescribed 84,053 items for lipid-regulating drugs at £1.20 per item, below England (£1.86), Maidstone (£1.62) and NHS Kent and Medway ICB (£1.90). Spend was £55,475 less than at England's unit cost across those items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+20.72%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.33%
Asthma prevalence, PCN 3-yr % change
Asthma reviews reached 69.5% (England 65.7%, Maidstone 63.2%) with a 3-year change of +20.7% (England +4.4%), leaving 666 patients on the 2,185 register without a recorded review. Asthma prescribing for ages 5–19 is 1,484 items per 1,000 (Maidstone 1,220), while second-hand smoking status recording is 75.0% (England 78.8%). COPD prevalence is 1.6% (572 patients; England 1.9%) with reviews at 75.9% and a 3-year change of +15.1% (England +2.8%). An unadjusted model suggests a benchmark register gap of +68 to +127 patients.
Cancer register and children's immunisation
Cancer prevalence is 5.2% (1,931 patients; England 3.8%, Maidstone 4.3%). In Q1 2025/26, MMR dose 1 coverage at age 5 reached 95.5% (0.5 pp above the 95.0% target), but MMR dose 2 was 84.1% (10.9 pp below target), an 11.4 pp difference between doses in the cohort. The 4-in-1 pre-school booster reached 80.7% (14.3 pp below target).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of cancers with a known stage in NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (4,661 of 8,384), in line with England (55.3%) but 19.4 pp below the 75.0% national ambition by 2028. Staging was recorded for 63.6% of registered cancers (8,384 of 13,189; England 67.0%), requiring 1,627 extra early diagnoses across the ICB to achieve 75%. Staging data is ICB-level rather than PCN performance, and small numbers limit site comparisons. PCN cancer prevalence is 5.2% (1,931 patients; England 3.8%). Cervical screening is 75.3% (England 66.8%), though Sutton Valence Group Practice is lower at 67.8%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Maidstone and Tunbridge Wells NHS Trust met all three cancer standards: 87.4% on 62-day referral to treatment (standard 85.0%), 81.8% on 28-day faster diagnosis (standard 75.0%), and 98.3% on 31-day combined treatment (standard 96.0%). Across NHS Kent and Medway Integrated Care Board, 62-day compliance was 75.9% (England 71.2%), while Medway NHS Foundation Trust achieved 81.6% and East Kent Hospitals University NHS Foundation Trust reached 70.0%. For diagnostic waits over 6 weeks, Maidstone and Tunbridge Wells NHS Trust recorded 0.9% for MRI and 0.5% for CT, but 19.8% for colonoscopy (England 30.8%).
| Pathways within standard (%) | Maidstone and Tunbridge Wells | Medway | East Kent | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 77.77 | 71.28 | 76.78 | 79.32 |
| 31-day treatment (96%) | 98.35 | 99.62 | 96.67 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 81.64 | 70.01 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | Medway | East Kent | England |
|---|---|---|---|---|
| MRI | 0.92 | 0.68 | 47.58 | 21.40 |
| CT | 0.51 | 0.00 | 37.45 | 9.92 |
| Echocardiography | 2.57 | 36.62 | 14.17 | 28.48 |
| Colonoscopy | 19.80 | 1.88 | 9.58 | 30.83 |
| Gastroscopy | 24.03 | 3.32 | 22.16 | 29.02 |
| All 15 DM01 tests | 6.42 | 14.20 | 48.38 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In Jun 2026, 65.8% of community health service contacts for Maidstone borough residents were with adults aged 65 and over (138,250 of 210,170 contacts). With 24.5% of THE RIDGE PCN's registered population aged 65+ (9,044 patients; England 17.9%), local community services may face substantial demand from older patients requiring ongoing supportive care, although activity is published at borough rather than PCN level.
Practice variation and patient experience
Phone access spans a 65.1 pp spread across the PCN's four practices
In 2025/26, overall QOF achievement ranged from 68.5% at Sutton Valence Group Practice and 83.3% at Len Valley Practice to 94.5% at Bearsted and 99.0% at Langley (England 92.5%). Vaccination achievement spanned 75.4 pp, from 15.6% at Sutton Valence Group Practice to 91.0% at Langley. Practice audits could test whether recall or recording differences explain these variations.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Langley | 115 | 7.0 | 96.5% | 79.2% | 97.6% |
| Bearsted | 105 | 0.0 | 66.2% | 68.4% | 87.8% |
| Sutton Valence | 115 | 0.0 | 58.6% | 62.4% | 79.5% |
| Len Valley | 101 | 0.0 | 31.4% | 80.1% | 60.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Hypertension treatment to target fell 5.2% over three years (England +3.6%)
Hypertension treatment to target fell 5.2% over three years (England +3.6%, Maidstone +0.7%), leaving current control at 65.0% against 70.3% in England. Blood pressure control also fell 1.8% for patients aged under 80 (England +3.2%) and 3.1% for those aged 80 and over (England +2.2%). Conversely, asthma reviews rose 20.7% over three years (England +4.4%) to 69.5% (England 65.7%), and diabetes control without frailty rose 9.1% (England +4.4%) to 62.2% (England 57.4%). This pattern is consistent with uneven review prioritisation across conditions, unverified locally and testable by clinical audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Hypertension treated to target
BP control, 80+
BP control, under 80
Diabetes statin (CVD)
Breast screening (53-70)
Asthma reviews
QRISK statin treatment
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Maidstone | Asset | PCN | Maidstone |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (780 beds) | n/a | Schools (catchment) | 40 | n/a |
| Children's centres | no data | 7 | Places of worship | 40 | 94 |
| Libraries | 3 | 9 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | n/a | 3 |
| Children and young people (VCS) | 1 | 3 | Carers support groups (VCS) | 1 | 4 |
| Primary schools (LA maintained) | 13 | 28 | Primary academies | 4 | 14 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension and lipid escalation review
On the 6,437 hypertension register (17.4%), 65.0% are treated to target (England 70.3%, Maidstone 69.7%) after a -5.2% 3-year change (England +3.6%); QRISK ≥ 20% lipid therapy is 55.0% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 88), age-5 MMR2 is 84.1% (11.4 pp below MMR1 at 95.5%; 10.9 pp below the 95.0% target) and 4-in-1 booster coverage is 80.7% (14.3 pp below target). For discussion: practices could validate age-5 cohorts and run flexible pre-school catch-up reminders for second-dose MMR and 4-in-1 boosters. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
COPD and heart failure case-finding
COPD prevalence is 1.6% (572 patients vs Maidstone 1.7%, England 1.9%; unadjusted gap +68 to +127) and heart failure is 0.8% (293 vs 0.9% and 1.1%; gap +44 to +112). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older population anticipatory care (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Cardiovascular treatment titration review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Telephony and triage operational review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension and lipid escalation review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Pre-school booster and MMR2 recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · COPD and heart failure case-finding (p12) | COPD register · COPD: QOF prevalence · Heart failure register | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
